Peer-reviewed article
On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.
Abstract
Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression<sup>1</sup> suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticlePsilocybin
Association of Psilocybin Use in Adolescents with Major Depressive Episode
ArticlePsilocybin
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
ArticlePsilocybin